Kevin Du, MD, PhD, MSCI
Associate Professor of Therapeutic RadiologyCards
About
Research
Publications
2026
Curietherapy User eXperience pilot study (CurieUx): a feasibility study of a novel augmented reality educational tool during radiation oncology consultation for patients with breast cancer
Byun D, Liu E, Maisonet O, Xiao J, Du K, Gerber N. Curietherapy User eXperience pilot study (CurieUx): a feasibility study of a novel augmented reality educational tool during radiation oncology consultation for patients with breast cancer. International Journal Of Radiation Oncology • Biology • Physics 2026 PMID: 41539575, DOI: 10.1016/j.ijrobp.2025.12.057.Peer-Reviewed Original ResearchRadiation oncology consultationOncology consultationBurden of cancer treatmentPsychological burdenBreast cancerRadiation knowledgeEducational toolPilot qualitative studyLikert scale surveySemistructured interviewsQualitative studyFeasibility studyPatient anxietyPositive experiencesConsultationPilot studyScale surveyAnxietyProof-of-concept studyBreastConsultation practiceTreatment machinePatient-specific anatomyComponents of anxietyMultiple domains
2025
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. The Oncologist 2025, 30: oyaf271. PMID: 40972532, PMCID: PMC12526980, DOI: 10.1093/oncolo/oyaf271.Peer-Reviewed Original ResearchBR-PDAC patientsStereotactic body radiotherapyBR-PDACR-PDACNeoadjuvant therapyR0 resectionSurgical resectionOverall survivalResection rateSingle arm phase 2 studyBorderline resectable pancreatic adenocarcinomaBorderline resectable PDACLocalized Pancreatic CancerResectable pancreatic adenocarcinomaSurgical resection rateR0 resection rateResidual microscopic diseasePhase 2 studyMedian OSGemcitabine/nab-paclitaxelPerioperative therapyResectable PDACMicroscopic diseaseOptimal regimenPrimary endpointPIVKA-II as an Adjunct Biomarker to AFP for the Assessment of the Early Radiographic Treatment Response to SBRT in HCC
Sil S, Banson K, Singh A, Xiao J, Hewitt D, Sacks G, Silk M, Wolfgang C, Du K, Mahadevan A, Hill C. PIVKA-II as an Adjunct Biomarker to AFP for the Assessment of the Early Radiographic Treatment Response to SBRT in HCC. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e696. DOI: 10.1016/j.ijrobp.2025.06.3068.Peer-Reviewed Original ResearchArterial phase hyper-enhancementStereotactic body radiationPIVKA-II levelsElevated alpha-fetoproteinPIVKA-IIPost-SBRTMacrovascular invasionTumor sizePre-SBRTAlpha-fetoproteinHepatocellular carcinomaMedian decreaseLR-TRExtrahepatic diseaseRadiographic assessmentChild-Pugh class AClinical utilityElevated PIVKA-IIMedian SBRT doseMedian tumor sizeInstitution retrospective studyVitamin K absenceMedian Follow-UpSerum alpha-fetoproteinMagnetic resonance imaging
2024
Assessing Dose Response and Patterns of Failure in Patients with Node Negative Anal Squamous Cell Carcinoma
Banson K, Fuligni G, Oh C, Domogauer J, Du K, Hill C, Mahadevan A, Xiao J, Shaikh F. Assessing Dose Response and Patterns of Failure in Patients with Node Negative Anal Squamous Cell Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e429-e430. DOI: 10.1016/j.ijrobp.2024.07.958.Peer-Reviewed Original ResearchLocal recurrence free survivalProgression free survivalOverall survivalPatterns of failureConcurrent chemoradiationDistant metastasisElective nodesPrimary siteFree survivalAnal cancerDe-EscalationPatients treated with concurrent chemoradiationHigh risk of local failureAnal squamous cell carcinomaAssociated with advanced T stageRisk of local failureHigh riskMultivariate Cox regression analysisAUC analysisDose responseDose de-escalationTreated with IMRTT1-T2 tumorsDose to tumorInstitution retrospective studyTreatment Outcomes and Toxicity of Chemoradiation in HIV Positive Patients with Anal Squamous Cell Carcinoma in the Modern Era
Fuligni G, Banson K, Oh C, Domogauer J, Du K, Hill C, Mahadevan A, Xiao J, Shaikh F. Treatment Outcomes and Toxicity of Chemoradiation in HIV Positive Patients with Anal Squamous Cell Carcinoma in the Modern Era. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e444. DOI: 10.1016/j.ijrobp.2024.07.988.Peer-Reviewed Original ResearchAnal squamous cell carcinomaLocal recurrence free survivalColostomy free survivalProgression free survivalHIV+ patientsSquamous cell carcinomaFree survivalAnal cancerOverall survivalPersistent cytopeniasCell carcinomaViral loadAcute toxicity grade 2Pretreatment CD4 cell countIncidence of anal cancerDose-reduced chemotherapyToxicity grade 2Toxicity of chemoradiationCD4 cell countDose to tumorHIV-positive patientsTreated with chemoradiationAnal cancer screeningRecurrence free survivalRetrospective dataPerioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2023
Understanding Treatment Anxiety and Utility of Mixed Media Educational Tools in Radiation Oncology Consultation: A Qualitative Study
Liu E, Fuligni G, Maisonet O, Xiao J, Du K, Gerber N, Byun D. Understanding Treatment Anxiety and Utility of Mixed Media Educational Tools in Radiation Oncology Consultation: A Qualitative Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e247. DOI: 10.1016/j.ijrobp.2023.06.1183.Peer-Reviewed Original ResearchRadiation oncology consultationPatient needsOncology consultationThematic analysisInitial consultationPatient education toolsDifficulty remembering informationWhole breast irradiationTreatment-related anxietyExperience of consultantsInitiation of treatmentTime of consultationTreatment set-upHealth literacyEducational toolHealthcare teamPatient experiencePatient educationRadiation consultationBreast irradiationTreatment anxietyHealth conditionsQualitative studyVisual aidsSemi-structured mannerCurietherapy User eXperience Pilot Study: A Novel Augmented Reality Educational Tool during Radiation Oncology Consultation for Patients with Breast Cancer
Byun D, Liu E, Maisonet O, Xiao J, Du K, Gerber N. Curietherapy User eXperience Pilot Study: A Novel Augmented Reality Educational Tool during Radiation Oncology Consultation for Patients with Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s19-s20. DOI: 10.1016/j.ijrobp.2023.06.241.Peer-Reviewed Original ResearchRadiation oncology consultationBreast cancer patientsBreast cancerCancer patientsOncology consultationSemi-structured interviewsLocalized Breast CancerRadiation oncology treatmentsBreath-hold techniqueIRB-approved studyRadiation consultationT1-T2N0Radiation knowledgeTreatment machineEducational toolPatient-specific anatomyOncological treatmentPilot qualitative studyInitial consultationPatientsCancer treatmentLikert scale surveyNIH PROMISTherapy consultationProne techniqueAnalysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, Wu A, Du K, Seaward S, Bian S, Aljumaily R, Shivnani A, Knoble J, Crocenzi T, DiPetrillo T, Roof K, Crane C, Goodman K. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology • Biology • Physics 2023, 118: 107-114. PMID: 37598723, PMCID: PMC10843017, DOI: 10.1016/j.ijrobp.2023.08.014.Peer-Reviewed Original ResearchConceptsTarget volumeRadiation therapy quality assuranceRadiation therapyPlanning target volumeClinical treatment volumeGross target volumePretreatment QAContouring atlasTreatment planningResectable pancreatic head adenocarcinomaRT planningIntensity modulated RTQA analysisPancreatic head adenocarcinomaNRG Oncology RTOGPracticing radiation oncologistsReal-time quality assuranceTreatment volumeEffects of RTConcurrent fluoropyrimidineConformal RTAdjuvant chemotherapyRadiation oncologistsQuality assurancePancreas cancerRadiation Oncology Providers' Practices and Preferences for Delivering Patient Education on Radiation Therapy: A Mixed Methods Study
Chen J, Bredesen R, Cooper S, Du K, Garda A, Janchenko L, Kim E, McAvoy S, Truong M, Patel M, Perni S, Rooney M, Schone S, Shiue K, Tonning K, Warren L, Golden D, Laucis A, Croke J, Group R. Radiation Oncology Providers' Practices and Preferences for Delivering Patient Education on Radiation Therapy: A Mixed Methods Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: e3-e4. DOI: 10.1016/j.ijrobp.2023.03.006.Peer-Reviewed Original ResearchPatient education practicesPatient education materialsPatient educationRadiation Oncology Education Collaborative Study GroupOncology providersEducational materialsIn-personRadiation oncology providersPatient education resourcesLack of timeMixed methods studyInadequate leadership supportWeb-based surveyProvider practicesPatient understandingProvider approachEducation Working GroupLeadership supportActivity educationThematic analysisMethods studyDescriptive statisticsVirtual visitsRadiation treatment processQualitative responses
Clinical Trials
Current Trials
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
IRB ID2000031055RoleSub InvestigatorPrimary Completion Date02/28/2026Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Kevin Du, MD, PhD, is a radiation oncologist who specializes in therapeutic radiology, with a focus on breast cancer and gastrointestinal radiotherapy. He is dedicated to improving cancer care through innovative treatment approaches, including organ preservation techniques and clinical trials aimed at enhancing patient quality of life.
Dr. Du believes in tailoring cancer treatments to meet the individual needs of his patients, leveraging cutting-edge biology and technology. He expresses a strong commitment to his patients, saying, "the incredible opportunity to learn about my patients' lives, what is important to them, and to help them in a time of crisis," is his favorite part of the job.
Dr. Du is an associate professor at Yale School of Medicine, where his work emphasizes the importance of clinical trials in developing new cancer therapies, particularly for challenging conditions like stomach cancer.
“While I can’t guarantee what will happen in the long run, I can guarantee that I will give you the best care possible, and that I will help you in any way I can,” he says.
Dr. Du completed his medical training and doctoral degree at the University of Pennsylvania and a residency in radiation oncology at the Hospital of the University of Pennsylvania.
Clinical Specialties
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineProstate Cancer
Learn More on Yale MedicineBreast Cancer
Learn More on Yale MedicineSmall Intestine Adenocarcinoma
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- March 24, 2026
AI in Cancer Workshop: Advancing Precision Medicine through Interdisciplinary Innovation
- October 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASTRO Annual Meeting
- May 12, 2025
Smilow Cancer Hospital Gastrointestinal Oncology Expertise in Fairfield County
- April 01, 2025
Comprehensive Breast Cancer Care at Smilow Cancer Hospital in Trumbull, Fairfield, and at Bridgeport Hospital
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.